Korea's Samsung And Pfizer In Genome Research Partnership To Fight Liver Cancer
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A month after an announcement about entering the biosimilars sector, South Korea's leading conglomerate, Samsung Group, is gearing up to get a stronger foothold in the pharmaceutical industry through establishing connections with established players
You may also be interested in...
Korea's Samsung Electronics Hopes To Expand Healthcare Footprint By Taking Over Device Firm
SEOUL - Five months after entering the healthcare industry, South Korea's Samsung Electronics is moving forward by signing a letter of intent to take over domestic medical equipment firm Medison Co
Korea's Samsung Electronics Hopes To Expand Healthcare Footprint By Taking Over Device Firm
SEOUL - Five months after entering the healthcare industry, South Korea's Samsung Electronics is moving forward by signing a letter of intent to take over domestic medical equipment firm Medison Co
Samsung Group Set To Enter Biosimilars Market With $1.9 Billion Investment
SEOUL - Samsung Group has ended years of exploration for new business realms beyond its traditional pipeline of semiconductors and electronics products; South Korea's leading conglomerate is set to enter the healthcare sector, particularly biosimilars and medical devices, with an initial investment of roughly $4.1 billion